Biopharmacopae secures investment to launch cosmeceuticals line
The science-based research and development outfit says it has secured the investment from Aviro to help it commercialize and further develop cosmeceutical and nutraceutical ingredients and end products.
The platforms for both categories have been developed using the company’s patented eXcelerate process, which is said to expedite the discovery and development process for plant based bioactive extracts, in turn providing a sustainable technology platform, the company says.
Targeting the health category
Biopharmacopae says the investment will help it to continue work with other strategic partners that will enable it to incorporate its plant-based natural active ingredient and products into consumer products in the health category.
“The company is well positioned to be a provider of a large suite of novel natural ingredients and end products to its strategic partners in the natural personal care and nutraceutical industries,” said Aki Georgracacos, partner in Aviro Ventures.
Dr Johane Guay, CEO of Biophamacopae says that it had specifically chosen to partner with Aviro because of its understanding of the food technology, nutraceutical and cosmeceutical categories, and the specific regulatory requirements that govern it.
Making the big step
Citing the main reasons why the company is now eyeing the big step from the research and development stage to commercialization, Guay said:
“There continues to be a growing demand by consumers for nutraceutical and cosmeceutical products that offer scientifically proven health benefits which are of high quality and based from non-chemical, natural ingredients. We offer our partners the innovation and proof of concept that is required to bring novel products to market efficiently.”
A study published at the end of 2006 by Kline & Company found that the global nutricosmetics market was valued at $1bn, a figure the company says is set to double over the next five-year period with Euromonitor claiming it had already grown by 50 per cent between 2002 and 2006.
